To compare hemodynamics and plasma big endothelin levels in patients awaiting heart transplantation who are receiving continuous IV therapy, and to establish their respective potency for predicting future cardiac events. Design: A randomized, prospective trial of ambulatory continuous treatment with IV prostaglandin E 1 (PGE 1 ) vs dobutamine. A subanalysis was conducted of all patients who completed 4 weeks of follow-up in regard to treatment effects on hemodynamics and big endothelin plasma levels. Patients: Thirty-two listed heart transplant candidates who were refractory to oral treatment, 21 patients who were receiving PGE 1 , and 11 patients receiving dobutamine. 
H
eart failure patients who are placed on the waiting list for heart transplantation may become refractory while their condition is being maintained by administering digitalis, diuretics, nitrates, and maximal tolerated doses of angiotensin-converting enzyme (ACE) inhibitors. Such patients often present with hypotension, low cardiac output, or overt clinical heart failure. In this setting, when immediate intervention is mandatory, a short period of IV inotropic therapy is often a very effective approach. 1 In specific patients, severe vasoconstriction may limit the rise in blood flow and can be effectively reversed by the use of IV vasodilators. It seems that the capability for carefully manipulating and combining agents for use in both inotropic and vasodilator actions has improved our ability to manage previously refractory patients. In a subset of patients, however, conditions may again deteriorate if weaning from IV infusions is attempted. Such patients can be treated in the outpatient setting or at home with indwelling central venous catheters and portable automatic pumps. As a temporary bridge to heart transplantation, these patients commonly receive infusions with dobutamine and/or vasodilators to stabilize their hemodynamics and to relieve symptoms. 2 Although research has focused on this field, the prognosis remains difficult to assess in this population. In patients with heart failure, both neurohumoral plasma levels at rest and peak oxygen consumption during exercise have proven to be significant as noninvasive prognostic indicators. 3 Specifically, levels of big endothelin, which accumulates in the circulation of patients who have high filling pressures, not only reflected the clinical severity of the disease, but also predicted 1-year heart failure mortality rates better than previously established prognostic indexes. 4 -6 In a study of elective heart transplantation candidates, big endothelin plasma levels were more useful in identifying patients who are at the highest risk of death or who are most in need of emergency transplantation than levels of peak oxygen consumption during exercise. 7 However, little information is available if a given cut-off level (calculated from one-point analysis) retains its prognostic significance after intensified heart failure therapy.
Recently, a prospective study was performed to evaluate the clinical outcomes of patients receiving long-term dobutamine, prostacyclin, or prostaglandin E 1 (PGE 1 ) infusions prior to heart transplantation. 8 The present investigation was performed in the subset of 32 patients who participated in the PGE 1 or dobutamine arm of this trial for a minimum of 4 weeks to gain new prognostic information from the data obtained during repeat right-heart catheterization as well as from serial plasma big endothelin levels. The study was specifically designed to assess the predictive power of hemodynamics as opposed to big endothelin plasma levels for future outcomes after 4 weeks of continuous IV treatment.
Materials and Methods

Patients
Thirty-two patients with advanced heart failure that was refractory to oral medications were enrolled. All patients were listed for heart transplantation. Entry criteria were as follows: a New York Heart Association designation, functional class IV; left ventricular ejection fraction, Յ 25%; cardiac output, Յ 2.5 L/min/m 2 ; and pulmonary capillary wedge pressure, Ն 20 mm Hg. Furthermore, patients had to have clinical signs of venous congestion despite receiving optimal orally administered medications, including digitalis, diuretics, ACE inhibitors, and oral anticoagulants. ACE inhibitors were given at the maximum tolerated dose. Additionally, eight patients were treated with amiodarone (four patients in the PGE 1 group and four patients in the dobutamine group). The clinical characteristics are listed in Table 1 .
Randomization and Treatment Protocol
The patient population is a subgroup of 68 patients participating in a parallel-group randomized trial comparing IV treatment with PGE 1 vs dobutamine vs prostacyclin. 8 All patients gave written informed consent and the protocol was approved by the Human Ethics Committee of the University of Vienna. The protocol of this trial has been reported previously. 8 After randomization, 30 patients received PGE 1 , 30 patients received dobutamine, and 8 patients received prostacyclin.
Patients were admitted to the ICU for at least 2 days. Right heart catheterization was performed with a flow-directed, balloon-tipped Swan-Ganz catheter. Cardiac output was calculated with a thermodilution computer. Arterial BP was recorded invasively from the radial artery. Hemodynamic indexes were calculated according to standard formulas.
The patients were randomized to either treatment group after baseline hemodynamic measurements. PGE 1 or dobutamine were delivered into the superior vena cava as continuous IV infusion. During the inpatient phase, PGE 1 was administered at a maximum dose of 40 ng/kg/min, dobutamine was administered at a maximum dose of 7.5 g/kg/min. A combined study end point for the inpatient dose-finding phase was defined by the following: (1) the inability of the cardiac index to increase by Ն 20%; (2) the absence of a substantial reduction in pulmonary vascular resistance index to Յ550 dyne ⅐ s ⅐ cm Ϫ5 /m 2 ; (3) the occurrence of adverse events, namely, death, worsening heart failure, and intolerable drug-related adverse events. Known PGE 1 -related side effects such as pain and flushing were not end points in this study, as long as they were considered tolerable by the patient. Patients who reached an end point were not included into the outpatient phase of the study. As described previously, 8 the efficacy of prostacyclin was inferior to that of PGE 1 . The prostacyclin arm of the study was truncated at interim analysis by the ethics committee at the University of Vienna based on the results of the Flolan International Randomized Trial 9 and on the preliminary outcomes of the eight patients. Actually, only 4 of 8 patients passed the inpatient phase. Therefore, only the remaining four patients received ambulatory continuous treatment with prostacyclin. During the outpatient phase, three patients developed worsening heart failure and one patient developed severe, intolerable headaches. Thus, all eight patients reached an end point. No patient from the prostacyclin arm of the study was included in the present subanalysis.
Ambulatory continuous IV drug infusion was given via a Hickman catheter placed in the subclavian vein. The starting dose for the ambulatory protocol was the dose at the end of the inpatient phase. Originally, 43 of 60 patients were enrolled into two arms of the ambulatory protocol, with 26 patients receiving PGE 1 and 17 patients receiving dobutamine. A combined study end point for the ambulatory study phase was defined by the following criteria: (1) worsening heart failure, including the need of additional treatment; (2) death; and (3) occurrence of serious adverse events. Eleven patients reached an end point within 28 days of treatment and were, therefore, not included in the present analysis. Thirty-two of 43 patients had an event-free course during the first 28 days of treatment and were enrolled in the present study.
Patients were on high-dose ACE inhibitors and diuretics, when starting IV therapy (Table 1) . During the 4 weeks of ambulatory, continuous IV therapy, the dose of ACE inhibitors and digitalis was not changed. The daily furosemide dose was not fixed but was adjusted on a short-term basis to maintain a stable body weight. In the two patients in the dobutamine group who received carvedilol or ␤-blockers, these drugs were withdrawn. In the three patients in the PGE 1 group who received carvedilol, therapy was maintained unchanged throughout the study.
Blood Sampling and Big Endothelin Assay
Venous blood samples were taken immediately before randomization and after 7, 14, 21, and 28 days of treatment. After 20 min of rest in a supine position, venous blood samples were obtained in precooled polyethylene tubes containing ethylenediaminetetraacetic acid (5 mol/mL blood). Test tubes were placed on ice and were centrifuged immediately at 4°C. Plasma samples were stored at Ϫ70°C until analyzed. Big endothelin levels in plasma were measured as immunoreactive big endothelin (C-terminal fragment big endothelin) by an extraction-based radioimmunoassay as described previously. 5 The antibody has been raised against the C-terminal fragment big endothelin and has 100% reactivity with big endothelin, 82% with the C-terminal fragment of big endothelin, and Ͻ 1% with endothelin 1, 2, and 3. The sensitivity of the assay is 0.7 fmol/mL. The linear range of the calibration curve extends from 1 to 17 fmol/mL. Our reference range is 0.8 to 1.8 fmol/mL.
Statistical Analysis
Continuous variables are expressed as mean Ϯ SD. The twotailed Student's t test was used for group comparisons of continuous variables, and Fisher's Exact Test was used for categoric variables. The Spearman rank correlation coefficient was computed to assess correlation between continuous variables. Repeated-measures analysis of variance (ANOVA) was used to analyze the time course of big endothelin plasma levels and hemodynamics during treatment. The starting values at time 0 were included in the analysis. The treatment effect was analyzed in performing a conventional one-way ANOVA. For the interaction between treatment and time, a correction for the multisample asphericity was used. A Cox proportional hazard regression analysis was performed to identify independent predictors of future outcome after 4 weeks of treatment. The model was built stepwise, and the p value for entering and staying in the model was set at 0.05. All hemodynamic variables measured at baseline and at 12 h and 4 weeks after the beginning of treatment, and all big endothelin plasma levels measured at day 0, 1, 7, 14, 21, and 28 of therapy were entered. Furthermore, all changes in variables between baseline and week 4 (ie, the delta) were entered. Kaplan-Meier survival estimates and the log-rank test were used to compare event-free survival between groups. A p value of Ͻ 0.05 was considered statistically significant. For all statistical analysis, computer software was used (SAS, version 7; SAS Institute; Cary, NC). Table 1 summarizes demographic and clinical characteristics as well as the concomitant oral therapy for the 32 patients studied. At baseline, the treatment groups were similar with respect to key demographic and clinical characteristics as well as hemodynamics, big endothelin plasma levels, and concomitant oral treatment. All patients were treated for Ն 28 days with ambulatory continuous IV drug therapy. None of the 32 patients studied had an event before the 28th day of treatment.
Results
Patient Characteristics
Clinical Outcome by Treatment Group
Twenty-one patients were randomized to PGE 1 . The dosage of PGE 1 at the start of ambulatory therapy was 10.4 Ϯ 4.8 ng/kg/min and was continuously reduced to 6.1 Ϯ 2.7 ng/kg/min after 28 days (p Ͻ 0.05). Body weight remained unchanged throughout the study period (78.7 Ϯ 10.8 vs 78.4 Ϯ 10.2 kg; not significant [NS]), whereas the furosemide dose decreased significantly (156 Ϯ 206 vs 96 Ϯ 53 mg/d; p Ͻ 0.05). The mean duration of treatment was 123 Ϯ 72 days. Eight patients were successfully bridged to heart transplantation after a median time of 97 days (range, 32 to 198 days), and seven patients were weaned successfully from PGE 1 treatment after a median time of 176 days (range, 61 to 265 days). At the closing date of the study, one patient was still waiting for transplantation. Four patients developed worsening heart failure after a median time of 64 days (range, 44 to 96 days), and one patient developed myalgia, arthralgia, and headache that was considered intolerable by the patient after 32 days of therapy.
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Eleven patients were randomized to dobutamine. The dosage of dobutamine at the start of ambulatory therapy was 4.5 Ϯ 2.0 g/kg/min and after 28 days of therapy was 3.9 Ϯ 1.0 g/kg/min (NS). Body weight remained unchanged throughout the treatment period (81.7 Ϯ 20.0 vs 79.6 Ϯ 18.0 kg; NS), and the furosemide dose remained unchanged as well (113 Ϯ 81 vs 108 Ϯ 70 mg/d; NS). The mean duration of treatment was 73 Ϯ 44 days. One patient was bridged successfully to heart transplantation after 96 days, and two patients were successfully weaned from dobutamine treatment after a median time of 121 (range, 114 to 128 days). Eight patients developed worsening heart failure after a median time of 39 days (range, 28 to 149 days).
Effects of Treatment on Hemodynamic Variables
The effects of PGE 1 and dobutamine on hemodynamic variables are shown in Table 2 . At baseline, the hemodynamics were similar in both groups. There was a significant correlation between right atrial pressure and plasma big endothelin levels at baseline (r ϭ 0.37; p Ͻ 0.05). After 12 h of therapy, the mean arterial BP, right atrial mean pressure, pulmonary artery mean pressure, pulmonary wedge pressure, systemic vascular resistance index (SVRI), and pulmonary vascular resistance index all decreased significantly in both treatment groups. The cardiac index increased significantly in both groups. After 4 weeks of therapy, the increase in cardiac index was sustained in both groups, whereas the decreases in the systemic and pulmonary vascular resistance indexes were sustained in the PGE 1 treatment group only. Overall, the magnitude of changes in the hemodynamic variables was similar in both groups after 12 h and 4 weeks of treatment, and hemodynamic variables did not differ between the PGE 1 and the dobutamine treatment group, either after 12 h or 4 weeks of treatment.
Effects of Treatment on Plasma Big Endothelin
The effects of PGE 1 and dobutamine on serial big endothelin plasma levels were evaluated using repeated-measures ANOVA (Table 3) . Big endothelin plasma levels decreased significantly in both treatment groups. However, the decrease in big endothelin plasma levels during treatment did not differ between the two groups.
Change of Plasma Big Endothelin Levels During 4 Weeks of Treatment According to Patient Outcome
The change in big endothelin plasma levels was assessed in 19 patients with event-free survival for 138 Ϯ 60 days and in 13 patients who suffered a serious event after 4 weeks of treatment (range, 28 to 149 days) ( Table 4 ). In 12 patients, this event was worsening heart failure that necessitated more aggressive forms of treatment; a single patient developed intolerable myalgia, arthralgia, and headache after 32 days of PGE 1 treatment. During the first 28 days of treatment, big endothelin plasma levels decreased to a greater extent in patients with a subsequent event-free course than in patients who suffered a serious event thereafter (p Ͻ 0.05).
Hemodynamic Changes After 4 Weeks of Treatment According to Patient Outcome
Changes in hemodynamic variables were assessed and compared in the 19 patients with future eventfree survival vs the 13 patients who suffered a serious event after 4 weeks of treatment (Table 5) . At baseline, the two groups did not differ significantly with respect to any hemodynamic variable. After 12 h of continuous treatment, mean arterial pressure, right atrial pressure, pulmonary artery pressure, pulmonary wedge pressure, SVRI, and pulmonary vascular resistance index decreased and cardiac index increased. After 4 weeks, a significant increase in cardiac index and decrease in SVRI were sustained in both outcome groups. However, the changes in both cardiac index and systemic vascular resistance were significantly different. Furthermore, the decrease in pulmonary arterial pressure and in pulmonary vascular resistance index was sustained only in the group of patients who remained event-free.
Prediction of Future Events After 4 Weeks of Treatment
Univariate and multivariate Cox proportional hazards models were used to predict future events after 4 weeks of treatment. No baseline parameter was found to contribute to prognosis in the model. In contrast, several variables measured after 4 weeks of treatment were significant predictors. On univariate analysis, plasma big endothelin ( 2 ϭ 10.8; p ϭ 0.001), pulmonary artery mean pressure ( 2 ϭ 6.4; p Ͻ 0.05), pulmonary wedge pressure ( 2 ϭ 5.6; p Ͻ 0.05), pulmonary vascular resistance index ( 2 ϭ 4.8; p Ͻ 0.05), and SVRI ( 2 ϭ 3.8; p ϭ 0.05). The respective changes between measurements at baseline and after 4 weeks of therapy for SVRI ( 2 ϭ 6.3; p Ͻ 0.05), cardiac index ( 2 ϭ 5.9; p Ͻ 0.05), and pulmonary artery pressure ( 2 ϭ 4.4; p Ͻ 0.05) all contributed significantly to the prediction of future events.
On multivariate stepwise forward regression analysis, only the following two independent predictors of future events were found: the plasma big endothelin level after 4 weeks of treatment (␤ ϭ 0.393; 2 ϭ 10.8; p ϭ 0.001; risk ratio, 1.48) and the SVRI after 4 weeks of treatment (␤ ϭ 0.003; 2 ϭ 6.9; p Ͻ 0.01; risk ratio, 1.003).
A receiver operating curve was built for the prediction of events using plasma big endothelin and SVRI, both measured after 4 weeks of treatment. By visual inspection of the curve, an arbitrary cutoff value of 4.3 fmol/mL plasma big endothelin and 2,300 dyne ⅐ s ⅐ cm Ϫ5 /m 2 SVRI was used for dichotomization. On reclassification, the dichotomized plasma big endothelin level accurately predicted future events in 23 of 32 patients (72%). Eighteen patients (14 event-free patients) had plasma big endothelin levels Ͻ 4.4 fmol/mL, and 14 patients (5 event-free patients) had plasma big endothelin levels Ͼ 4.3 fmol/mL. Event rates, as evaluated by a Kaplan-Meier lifetime analysis, were significantly lower in patients with plasma big endothelin levels Ͻ 4.4. fmol/mL (Fig 1) (p Ͻ 0.05 on log-rank test). The dichotomized SVRI predicted future events in 20 of 32 patients (63%). Fifteen patients (11 eventfree patients) had an SVRI Ͻ 2,300 dyne ⅐ s ⅐ cm 
Discussion
In patients with heart failure that is refractory to aggressive oral treatment, long-lasting changes in hemodynamics were achieved by continuous IV infusions of dobutamine or PGE 1 targeted to obtain symptom relief during the waiting period for heart transplantation. These desirable effects were accompanied by a gradual drop in big endothelin plasma levels. The present findings indicate that a reduction in the SVRI to Ͻ 2,300 dyne ⅐ s ⅐ cm Ϫ5 /m 2 or a reduction in plasma big endothelin levels to Ͻ 4.4 fmol/mL within a period of 4 weeks is associated with improved outcomes. Conversely, persistently elevated plasma big endothelin levels and/or a persistently elevated vascular resistance index strongly suggest a poor prognosis in the absence of symptoms that are suggestive of impending decompensation. Viewing heart failure as a vasoconstrictive state due to a variety of factors, including the abnormal imbalance of endothelial dilator/constrictor forces as well as high levels of circulating norepinephrine, angiotensin II, and vasopressin, it is not surprising that the SVRI did not simply reflect the prognostic importance of a single vasoconstrictor system in this study but had prognostic significance on its own.
Pathophysiologic Significance of Endothelin Stimulation
The actions of endothelin mimic the disturbing symptoms of advanced left ventricular dysfunction, such as pulmonary congestion, peripheral edema, and exercise intolerance. 10, 11 Furthermore, endothelin promotes deleterious structural processes in the heart and vessel wall leading to irreversibility of heart failure. [12] [13] [14] Conversely, experimental evidence suggests that the chronic use of endothelin antagonists might prolong survival after myocardial infarction, 15 and preliminary clinical studies have shown sustained improvements in patients with severe heart failure. 16 In this, as in previous reports, plasma levels of the prohormone big endothelin are used as a tool to assess the integrated secretory activity of endothelin-producing cells. The abnormally high big endothelin levels reported here could be the result of multiple mechanisms operative in patients with advanced left ventricular dysfunction, such as angiotensin II, norepinephrine, tumor necrosis factor-␣, or hypoxia occurring at multiple sites, including the large pulmonary endothelial surface or in circulating mononuclear cells. [17] [18] [19] [20] [21] Improved left ventricular loading conditions and a better hemodynamic profile resulting from continuous IV treatment are probably the major mechanisms for lowering big endothelin plasma levels that were found in the present study, which presumably occurred as a result of blunting some of the above-mentioned stimuli. 22, 23 
Potential Role of Big Endothelin Among Other Prognostic Indicators
In several studies, attention again has become focused on cardiac peptides, in particular the brain natriuretic peptide and the pro-brain natriuretic peptide, as indicators of left ventricular dysfunction and prognosis after myocardial infarction. 24 -26 However, data comparing the brain natriuretic peptide with big endothelin as a predictive marker in patients with advanced heart failure have not been reported. Since the brain natriuretic peptide is released in response to cardiac injury predominantly from the cardiac ventricles, and big endothelin is probably a Figure 1 . Kaplan-Meier analysis showing event-free survival in 32 listed candidates for heart transplantation after 4 weeks of ambulatory, continuous, long-term IV therapy. Patients were stratified into two groups according to plasma big endothelin levels after 4 weeks of uneventful therapy. Patients with lower plasma big endothelin levels had significantly better outcomes (p Ͻ 0.05).
Table 5-Hemodynamic Changes in Patients With Event-Free Survival Compared With Patients
Who Had Poor Outcomes* product of the vascular endothelium throughout the circulation, the plasma levels of both hormonal markers might provide valuable independent prognostic information to single out patients at highest risk. In summary, the present study demonstrates that measuring big endothelin plasma levels after continuous IV support may provide useful noninvasive clues to estimating therapeutic benefit and to guiding subsequent patient management.
